文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

作者信息

Ding Jianghua, Gong Shengping

机构信息

Department of Hematology and Oncology, Jiujiang University Affiliated Hospital, Jiujiang, China.

Department of Oncology, The First Affiliated Hospital of Ningbo University, Ningbo, China.

出版信息

Front Pharmacol. 2024 May 9;15:1398879. doi: 10.3389/fphar.2024.1398879. eCollection 2024.

DOI:10.3389/fphar.2024.1398879
PMID:38783962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11111930/
Abstract
摘要

相似文献

[1]
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

Front Pharmacol. 2024-5-9

[2]
Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma.

Ther Adv Hematol. 2021-9-30

[3]
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Lancet Oncol. 2020-8-28

[4]
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

Hematology Am Soc Hematol Educ Program. 2012

[5]
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations.

Br J Haematol. 2024-4

[6]
[Induction therapy of transplant-eligible patients in multiple myeloma].

Nihon Rinsho. 2015-1

[7]
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy.

Cancers (Basel). 2023-12-5

[8]
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

Transplant Cell Ther. 2023-3

[9]
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.

Lancet Oncol. 2023-1

[10]
Putting the best foot forward when treating newly diagnosed multiple myeloma.

Intern Med J. 2023-3

本文引用的文献

[1]
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

Lancet Haematol. 2023-10

[2]
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.

Clin Lymphoma Myeloma Leuk. 2023-6

[3]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[4]
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

Lancet Haematol. 2022-11

[5]
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

JAMA Oncol. 2022-9-1

[6]
Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.

Adv Ther. 2022-8

[7]
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Am J Hematol. 2022-8

[8]
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Adv Ther. 2022-5

[9]
Current approaches to management of newly diagnosed multiple myeloma.

Am J Hematol. 2022-5

[10]
How I treat high-risk multiple myeloma.

Blood. 2022-5-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索